<i id='BF1E14BAA8'><strike id='BF1E14BAA8'><tt id='BF1E14BAA8'><pre id='BF1E14BAA8'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
23andMe had bad news about my health. I wish a person had delivered it 
Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee 
Novavax promises a turnaround & Lilly roils the obesity market 
Annovis Bio delivers candor, but not confidence, on Parkinson’s study 
Medical leaders decry Supreme Court decision on affirmative action 
With competition flaring, obesity drug hits goal in liver disease study 
Continuity nursing helped my family in our darkest PICU moments 
Stem cell biologist probes earliest stages of human development 
Jerome Adams on the need for new antivirals for Covid 
New documents shed light on MD Anderson Cancer Institute feud 
Malaria cases in Florida and Texas: Here’s what you need to know 
He's a Nobel laureate. Critics say he was misleading on Covid 
Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies 
Pregnant women don't need prenatal multivitamins, study concludes 
Trump demands the U.S. pay no more for drugs than other countries … again 
